Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service – results from the prospective, multi-center, observational cohort study thrombEVAL

Table 3 Distribution of indication for oral anticoagulation (OAC) and corresponding time in therapeutic range in regular medical care and coagulation service

Indication for OAC	Regular medical care		Coagulation service
Indication for OAC	Frequency	Time in therapeutic range	Frequency	Time in therapeutic range
Atrial fibrillation	66.2% (1,332)	67.5% (49.3/83.3)	61.1% (464)	75.0% (61.8/77.3)
Deep vein thrombosis	6.1% (123)	65.2% (46.8/75.3)	14.2% (108)	75.3% (66.1/85.0)
Peripheral vascular bypass surgery	8.0% (160)	64.9% (47.1/81.2)	2.2% (17)	74.9% (61.8/77.3)
Prosthetic heart valve	9.7% (195)	42.2% (30.4/68.3)	7.4% (56)	76.8% (63.0/82.8)
Pulmonary embolism	7.7% (154)	66.5% (50.6/82.6)	13.3% (101)	75.5% (64.7/84.7)
Others*	5.0% (100)	70.1% (54.3/82.1)	5.0% (38)	79.2% (59.8/88.0)

Patients can have more than one indication for oral anticoagulation (OAC) with vitamin K antagonist; indication is described in 2,011 of patients in regular medical care and 760 patients in the coagulation service cohort. In coagulation service patients with pre-treatment in regular medical care, information on regular medical care pre-treatment are described within regular medical care cohort (non-disjunct data). Frequency of indication is depicted as relative and absolute frequency. Time in therapeutic range was calculated in patients with at least 4 months of anticoagulation treatment except self-management patients (1,160 patients in regular medical care and 560 patients in coagulation service, respectively). *e.g., cerebral venous sinus thrombosis, Paget-Schrötter disease.

ISSN: 1741-7015